Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis.

Abstract:

INTRODUCTION:Adverse drug events (ADEs) may represent an important item of expenditure for healthcare systems and their prevention could be associated with a relevant cost saving. OBJECTIVE:The objective of this study was to simulate the annual economic burden for ADEs in Tuscany (Italy) and the potential cost savings related to avoidable ADEs. METHODS:A systematic review was performed, according to the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) statements, on observational studies published from 2006 to 2016 in MEDLINE and EMBASE, focusing on direct costs of ADEs in the inpatient setting from high-income countries. The mean probability of preventable ADEs was estimated over the included studies. The mean ADE cost was calculated by means of Monte Carlo simulation. We then extrapolated the spontaneous reports of ADEs in Tuscany, Italy in 2016 from the Italian National Pharmacovigilance Network (Rete Nazionale di Farmacovigilanza), and we assumed the same costs and preventability probability for these as obtained in the systematic review. Finally, we simulated the possible costs of ADEs and preventable ADEs in Tuscany. Three sensitivity analyses were also performed to test the robustness of the results. RESULTS:Of 11,936 articles initially selected, 12 observational studies were included. The estimated mean [± standard deviation (SD)] ADE cost was €2471.46 (± €1214.13). The mean (± SD) probability of preventable ADEs was 45% (± 21). The Tuscan expenditure for ADEs was €3,406,280.63 per million inhabitants (95% confidence interval (CI) 1,732,910.44-5,079,664.61) and the potential cost saving was €1,532,760.25 per million inhabitants (95% CI 779,776.1-2,285,750.60). Sensitivity analyses confirmed the robustness of the results. CONCLUSIONS:The present simulation showed that ADEs could have a relevant economic impact on the Tuscan healthcare system. In this setting, the prevention of ADEs would result in important cost savings. These results could be likely extended to other healthcare systems.

journal_name

Drug Saf

journal_title

Drug safety

authors

Convertino I,Salvadori S,Pecori A,Galiulo MT,Ferraro S,Parrilli M,Corona T,Turchetti G,Blandizzi C,Tuccori M

doi

10.1007/s40264-018-0737-0

subject

Has Abstract

pub_date

2019-03-01 00:00:00

pages

427-444

issue

3

eissn

0114-5916

issn

1179-1942

pii

10.1007/s40264-018-0737-0

journal_volume

42

pub_type

杂志文章
  • Optimising outcomes in end-stage heart failure: differences in therapeutic responses between diverse ethnic groups.

    abstract::Clinical and pathophysiological differences between Japanese and Caucasian patients are observed in many aspects of heart disease. Indeed, data derived from studies in one population cannot be automatically extrapolated to the other. The therapeutic goal of heart failure has recently been aimed at improving mortality ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200427001-00004

    authors: Sasayama S

    更新日期:2004-01-01 00:00:00

  • Complications of regional anaesthesia Incidence and prevention.

    abstract::The complications of failure, neural injury and local anaesthetic toxicity are common to all regional anaesthesia techniques, and individual techniques are associated with specific complications. All potential candidates for regional anaesthesia should be thoroughly evaluated and informed of potential complications. I...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200124060-00002

    authors: Faccenda KA,Finucane BT

    更新日期:2001-01-01 00:00:00

  • Neurotoxicity of carbapenem antibacterials.

    abstract::Similar to other beta-lactam antibacterials, carbapenems have a neurotoxic potential that seems to be higher than that of the penicillins and cephalosporins. Seizures have been reported in several large studies of patients treated with imipenem/cilastatin. However, it seems clear that the main factor increasing the ri...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199615020-00001

    authors: Norrby SR

    更新日期:1996-08-01 00:00:00

  • Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies.

    abstract::Since 2008, the direct-acting oral anticoagulants (DOACs) have expanded the therapeutic options of cardiovascular diseases with recognized clinical and epidemiological impact, such as non-valvular atrial fibrillation (NVAF) and venous thromboembolism (VTE), and also in the preventive setting of orthopedic surgical pat...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-016-0464-3

    authors: Raschi E,Bianchin M,Ageno W,De Ponti R,De Ponti F

    更新日期:2016-12-01 00:00:00

  • Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.

    abstract::Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of certain forms of cancers, raising hopes for many patients with otherwise unresponsive tumours. While these agents are generally well tolerated, clinical experience with them has highlighted their unexpected association with serious toxic effects on...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-013-0050-x

    authors: Shah DR,Shah RR,Morganroth J

    更新日期:2013-06-01 00:00:00

  • Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication.

    abstract::Benefit-risk assessment should be ongoing during the life cycle of a pharmaceutical agent. New products are subjected to rigorous registration laws and rules, which attempt to assure the availability and validity of evidence. For older products, bias in benefit-risk assessment is more likely, as a number of safeguards...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200932040-00003

    authors: De Backer TL,Vander Stichele RH,Van Bortel LM

    更新日期:2009-01-01 00:00:00

  • Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis.

    abstract::Intranasal corticosteroids and intranasal antihistamines are efficacious topical therapies in the treatment of allergic rhinitis. This review addresses their relative roles in the management of this disease, focusing on their safety and tolerability profiles. The intranasal route of administration delivers drug direct...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200326120-00003

    authors: Salib RJ,Howarth PH

    更新日期:2003-01-01 00:00:00

  • Drugs dispensed in primary care during pregnancy: a record-linkage analysis in Tayside, Scotland.

    abstract:BACKGROUND:For many regularly used drugs, evidence for safe use in pregnancy has not been established. Despite this, international studies have identified high levels of drug prescribing among pregnant women. OBJECTIVE:To investigate the patterns of prescribing of drugs to women who gave birth in Tayside, Scotland, in...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11532330-000000000-00000

    authors: Irvine L,Flynn RW,Libby G,Crombie IK,Evans JM

    更新日期:2010-07-01 00:00:00

  • Assessment of Self-Administration of Romiplostim in Patients with Immune Thrombocytopenic Purpura after Receipt of Home Administration Training Materials: a Cross-Sectional Study.

    abstract:INTRODUCTION:Romiplostim is a subcutaneously administered thrombopoietin-receptor agonist approved in the European Union for self-administration (or administration by a caregiver) in selected adult patients with chronic primary immune thrombocytopenia refractory to other treatments. To mitigate the risk of medication e...

    journal_title:Drug safety

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s40264-018-0723-6

    authors: Schipperus M,Kaiafa G,Taylor L,Wetten S,Kreuzbauer G,Boshier A,Seesaghur A

    更新日期:2019-01-01 00:00:00

  • Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.

    abstract::Pharmacovigilance science has traditionally been a discipline focussed on the postmarketing or post-authorisation period, with due attention directed towards pre-clinical safety data, clinical trials and adverse events. As the biological sciences have evolved, pharmacovigilance has slowly shifted toward earlier, proac...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200629080-00003

    authors: Hartford CG,Petchel KS,Mickail H,Perez-Gutthann S,McHale M,Grana JM,Marquez P

    更新日期:2006-01-01 00:00:00

  • Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia.

    abstract::The purpose of this review is to assess the benefits and risks associated with the use of the ketolide antibacterial telithromycin, currently licensed for the treatment of adults with mild to moderate community-acquired pneumonia (CAP). Telithromycin is active against both the major (Streptococcus pneumoniae, Haemophi...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200831070-00002

    authors: Brown SD

    更新日期:2008-01-01 00:00:00

  • Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review.

    abstract::After 2002, an association between stroke and antipsychotic use was reported in clinical trials and large database studies. This review considers previous quantitative reviews, newly published clinical trials, and recent observational cohort and case-control studies, and focuses on the clinical significance of the ris...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/11319120-000000000-00000

    authors: Sacchetti E,Turrina C,Valsecchi P

    更新日期:2010-04-01 00:00:00

  • Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China.

    abstract:INTRODUCTION:Electronic healthcare databases (EHDs) are used increasingly for post-marketing drug safety surveillance and pharmacoepidemiology in Europe and North America. However, few studies have examined the potential of these data sources in China. METHODS:Three major types of EHDs in China (i.e., a regional commu...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-017-0589-z

    authors: Yang Y,Zhou X,Gao S,Lin H,Xie Y,Feng Y,Huang K,Zhan S

    更新日期:2018-01-01 00:00:00

  • The clinical implications of inhibition of the inducible form of cyclo-oxygenase.

    abstract::There are 2 isoenzymes of cyclo-oxygenase (COX). There is a constitutive enzyme COX-1 which has a wide tissue distribution. In addition there is an inducible enzyme COX-2 which has a restricted tissue distribution. The inducible enzyme COX-2 is responsible for the generation of prostaglandins at sites of tissue inflam...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199615040-00003

    authors: Richardson C,Emery P

    更新日期:1996-10-01 00:00:00

  • Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine.

    abstract:BACKGROUND:Atypical antipsychotics have been associated with metabolic abnormalities including impaired glucose metabolism, exacerbation of existing diabetes mellitus and new-onset type 2 diabetes. Not all atypical antipsychotic agents appear to have the same propensity to cause these complications. OBJECTIVE:To asses...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200730070-00004

    authors: Ramaswamy K,Kozma CM,Nasrallah H

    更新日期:2007-01-01 00:00:00

  • Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.

    abstract::Bisphosphonates are the primary pharmacological agents used for the management of osteoporosis and hypercalcaemia of malignant bone disease. The efficacy of these agents in these two conditions has been demonstrated in many well designed trials published over the past 2 decades. The variety of bisphosphonates currentl...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200629120-00005

    authors: Bobba RS,Beattie K,Parkinson B,Kumbhare D,Adachi JD

    更新日期:2006-01-01 00:00:00

  • Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest.

    abstract::The entire drug safety enterprise has a need to search, retrieve, evaluate, and synthesize scientific evidence more efficiently. This discovery and synthesis process would be greatly accelerated through access to a common framework that brings all relevant information sources together within a standardized structure. ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-014-0189-0

    authors: Boyce RD,Ryan PB,Norén GN,Schuemie MJ,Reich C,Duke J,Tatonetti NP,Trifirò G,Harpaz R,Overhage JM,Hartzema AG,Khayter M,Voss EA,Lambert CG,Huser V,Dumontier M

    更新日期:2014-08-01 00:00:00

  • Randomized controlled trials of COX-2 inhibitors: an analysis of doses used and trends over time to investigate implications for comparative safety.

    abstract:BACKGROUND:Naproxen, ibuprofen and diclofenac are frequently used as comparators in randomized controlled trials (RCTs) on the safety and efficacy of cyclooxygenase (COX)-2 inhibitors. Different comparator doses may influence the results of RCTs. It has been hypothesized that RCTs of COX-2 inhibitors where different do...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11590470-000000000-00000

    authors: Stefansdottir G,De Bruin ML,Knol MJ,Grobbee DE,Leufkens HG

    更新日期:2011-09-01 00:00:00

  • Correction to: Drug-Induced Dental Caries: A Disproportionality Analysis Using Data from VigiBase.

    abstract::Dental caries is defined as a pathological breakdown of the tooth. It is an infectious phenomenon involving a multifactorial aetiology. The impact of drugs on cariogenic risk has been poorly investigated. ...

    journal_title:Drug safety

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40264-018-0672-0

    authors: Patras de Campaigno E,Kebir I,Montastruc JL,Rueter M,Maret D,Lapeyre-Mestre M,Sallerin B,Despas F

    更新日期:2018-08-01 00:00:00

  • The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients.

    abstract:BACKGROUND AND OBJECTIVE:Many drugs that are used to treat children are either not licensed for use in paediatric patients (unlicensed) or prescribed outside the terms of the product licence (off label). The incidence of adverse drug reactions (ADRs) associated with the use of such drugs is yet to be established. This ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200427130-00006

    authors: Neubert A,Dormann H,Weiss J,Egger T,Criegee-Rieck M,Rascher W,Brune K,Hinz B

    更新日期:2004-01-01 00:00:00

  • Safety and Tolerability of Adoptive Cell Therapy in Cancer.

    abstract::Adoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g., tumor-infiltrating lymphocytes [TIL]) or T cells genetically engineered to confer antigen specificity (T-cell receptor [TCR] or chimeric antigen receptor [CAR] eng...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-018-0779-3

    authors: Wolf B,Zimmermann S,Arber C,Irving M,Trueb L,Coukos G

    更新日期:2019-02-01 00:00:00

  • Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting.

    abstract:INTRODUCTION:The use of mobile apps is increasing in medicine. In pharmacovigilance, mobile apps may help to increase adverse drug reaction reporting and improve the communication of safety issues. The Toulouse University Pharmacovigilance Center has developed VigiBIP®, a free smartphone app available on Android and Ap...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-017-0630-2

    authors: Montastruc F,Bagheri H,Lacroix I,Damase-Michel C,Chebane L,Rousseau V,Jouanjus E,Lapeyre-Mestre M,Durrieu G,Montastruc JL

    更新日期:2018-05-01 00:00:00

  • Comparative safety and efficacy of proton pump inhibitors in paediatric gastroesophageal reflux disease.

    abstract::Gastroesophageal reflux is one of the most common reasons for referrals to paediatricians or paediatric gastroenterologists. Gastric acid-buffering agents, mucosal surface barriers and gastric anti-secretory agents are the main groups of medications currently used for treating gastroesophageal reflux disease (GERD) in...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-014-0154-y

    authors: Kierkus J,Oracz G,Korczowski B,Szymanska E,Wiernicka A,Woynarowski M

    更新日期:2014-05-01 00:00:00

  • Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample.

    abstract:INTRODUCTION:Non-steroidal anti-inflammatory drugs are associated with a dose and duration-dependent coronary risk. There is little information concerning analgesic-dose ibuprofen, among the most widely used drugs worldwide. OBJECTIVE:Our objective was to measure the risks of acute coronary syndrome (ACS) after dispen...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-018-0686-7

    authors: Duong M,Abouelfath A,Lassalle R,Droz C,Blin P,Moore N

    更新日期:2018-11-01 00:00:00

  • Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.

    abstract:BACKGROUND AND OBJECTIVE:Rosuvastatin is a lipid-lowering drug, the newest of a class of drugs called HMG-CoA reductase inhibitors, or 'statins', launched in the UK in March 2003. Our objective was to monitor the post-marketing safety of this drug, prescribed in primary care in England, using prescription-event monitor...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200730020-00005

    authors: Kasliwal R,Wilton LV,Cornelius V,Aurich-Barrera B,Shakir SA

    更新日期:2007-01-01 00:00:00

  • Comment on: "All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population".

    abstract:: ...

    journal_title:Drug safety

    pub_type: 评论,信件

    doi:10.1007/s40264-018-0670-2

    authors: Kawada T

    更新日期:2018-06-01 00:00:00

  • Measles vaccination and inflammatory bowel disease: controversy laid to rest?

    abstract::The increasing incidence of Crohn's disease has lead to speculation about changes in exposures to environmental or infectious agents. Considerable attention has focused on the role of measles infection and/or vaccination in the pathogenesis of Crohn's disease and ulcerative colitis. Current evidence regarding the asso...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200124130-00001

    authors: Davis RL,Bohlke K

    更新日期:2001-01-01 00:00:00

  • Tolerabilities of antiretrovirals in paediatric HIV infection.

    abstract::Data on the efficacy and tolerability of antiretrovirals in children are limited as, in contrast to adult studies, large paediatric cohort studies are lacking. Thus, data pertaining to adults are often extrapolated to children despite the acknowledgement that children are not little adults. This review summarises info...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200225140-00001

    authors: Lemberg DA,Palasanthiran P,Goode M,Ziegler JB

    更新日期:2002-01-01 00:00:00

  • Cardiac effects of ebastine and other antihistamines in humans.

    abstract::The electrocardiographic effects of ebastine and its active metabolite, carebastine, have been studied alone and in relevant drug-interaction studies in various patient populations. The overall cardiac tolerability of ebastine is excellent. In ebastine dose-ranging studies in adults and children, there were no meaning...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199921001-00009

    authors: Moss AJ,Morganroth J

    更新日期:1999-01-01 00:00:00

  • National ADR Monitoring System in China.

    abstract::It has been more than 25 years since an adverse drug reaction (ADR) monitoring agency was first established in China. In the past few years, the National ADR Monitoring System (NADRMS) has developed rapidly in the country. However, this system has not been reviewed in detail in the literature. Our aim was to demonstra...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-016-0446-5

    authors: Hou Y,Li X,Wu G,Ye X

    更新日期:2016-11-01 00:00:00